Analysts Stocks

      Cantor Fitzgerald raises HIVE target to $4.6, stays Overweight

      Cantor Fitzgerald analyst Brett Knoblauch bumped up their price target on HIVE to $4.6 on May 19, with the rating unchanged at Overweight.

      On HIVE alone, Brett has made 12 documented calls, 7 of 12 eventually touched by the stock’s price.

      Among the analysts AnaChart tracks on HIVE, the split is 6 Buy. The target range spans Christopher Brendler at Rosenblatt ($5.5) to Bill Papanastasiou at Stifel ($11). HIVE last closed at $3.36.

      HIVE price target chart: Cantor Fitzgerald raises to $4.6
      HIVE price targets: Brett Knoblauch against the highest and lowest current targets on the stock, plotted with the price.

      The $4.6 target is 37% above the stock’s $3.36 close.

      FAQ

      What is Cantor Fitzgerald’s price target on HIVE?

      Cantor Fitzgerald’s Brett Knoblauch has a $4.6 target on HIVE, rated Overweight, set May 19, 2026.

      How often have Brett Knoblauch’s HIVE price targets been reached?

      AnaChart has tracked 12 price-target calls from Brett Knoblauch on HIVE; the stock reached the target in 7 of them (58%).

      What is the analyst view on HIVE?

      Coverage is split 6 Buy / 0 Hold / 0 Sell, with targets from $5.5 (Rosenblatt) to $11 (Stifel).